Business Description
Moleculin Biotech Inc
NAICS : 325412
SIC : 2834
ISIN : US60855D1019
Total Employee Number:
17Description
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 31.65 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 62.5 | |||||
3-Year EPS without NRI Growth Rate | 62.4 | |||||
3-Year FCF Growth Rate | 62.5 | |||||
3-Year Book Growth Rate | -81 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 54.39 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.38 | |||||
Quick Ratio | 1.38 | |||||
Cash Ratio | 1.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -247.9 | |||||
Shareholder Yield % | -179.33 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -139.85 | |||||
ROIC % | -217.44 | |||||
3-Year ROIIC % | 871.97 | |||||
ROC (Joel Greenblatt) % | -6257.64 | |||||
ROCE % | -184.8 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.93 | |||||
Price-to-Tangible-Book | 3.47 | |||||
EV-to-EBIT | -0.15 | |||||
EV-to-Forward-EBIT | -6.27 | |||||
EV-to-EBITDA | -0.15 | |||||
EV-to-Forward-EBITDA | -7.05 | |||||
EV-to-FCF | -0.17 | |||||
| Price-to-Net-Current-Asset-Value | 5.08 | |||||
| Price-to-Net-Cash | 6.6 | |||||
Earnings Yield (Greenblatt) % | -666.67 | |||||
FCF Yield % | -172.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Moleculin Biotech Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -24.043 | ||
| Beta | 0.9318 | ||
| 3-Year Sharpe Ratio | -0.07 | ||
| 3-Year Sortino Ratio | -0.09 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 161.25 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 161.25 - 161.25 | ||
| Shares Outstanding (Mil) | 7.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Moleculin Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Moleculin Biotech Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 131 days | ||
| General meeting for 2026 | 2026-08-18 10:00 | In 45 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 39 days | ||
| First quarter earnings conference call for 2026 | 2026-05-21 08:30 | 161.25 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-21 | 161.25 (+0.00%) | ||
| 38th Annual Roth Conference | 2026-03-24 12:00 | 161.25 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 | 161.25 (+0.00%) | ||
| Annual report for 2025 | 2026-03-18 | 161.25 (+0.00%) | ||
| Corporate Connect Webinar Series hosted by Webull Financial | 2026-02-11 13:20 | 161.25 (+0.00%) | ||
| Live Virtual Investor Closing Bell Series | 2025-12-02 16:00 | 161.25 (+0.00%) |
Show
Entries
Moleculin Biotech Inc Frequently Asked Questions
What is Moleculin Biotech Inc(FRA:MOL0)'s stock price today?
The current price of FRA:MOL0 is €161.25. The 52 week high of FRA:MOL0 is €161.25 and 52 week low is €161.25.
When is next earnings date of Moleculin Biotech Inc(FRA:MOL0)?
The next earnings date of Moleculin Biotech Inc(FRA:MOL0) is 2026-08-13 Est..
Does Moleculin Biotech Inc(FRA:MOL0) pay dividends? If so, how much?
Moleculin Biotech Inc(FRA:MOL0) does not pay dividend.
Press Release
Articles on Moleculin Biotech Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers